搜索结果


   MAPK3

靶点ID:TCMBANKGE001201


靶点别名:ERK-1; ERK1; ERT2; HS44KDAP; HUMKER1A; P44ERK1; P44MAPK; PRKM3; p44-ERK1; p44-MAPK


靶点描述:mitogen-activated protein kinase 3


染色体:16


染色体位置:16p11.2


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:6877


OMIM_Link:601795


Ensembl_Link:ENSG00000102882


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
TCMBANKHE003734 radix tripterygii wilfordii 雷公藤 To expel wind-dampness, relieve swelling, alleviate pain and dredge the meridian passage./Rheumatoid arthritis, rheumatic arthritis, glomerulonephritis, nephropathy syndrome, erythematous lupus, dryness in eyes and mouth, Behcet’s syndrome, psoriasis, eczema, leprosy, scab sore, intractable lichen. root, leaf and flower
TCMBANKHE003752 Radix Salviae liguliobae 丹参 To remove blood stasis and relieve pain, to promote the flow of blood and stimulate menstrual discharge, and to ease the mind./Angina pectoris, cerebral atherosclerosis, diffusive intravascular clotting, thrombophlebitis, hepatitis, acute surgical infection, mastitis, erysipelas, otitis media, tonsillitis, bone marrow infection, menstrual disorder, dysmenorrhea, amenorrhea, postpartum stasis stagnation abdominal pain, pain in heart and abdomen, concretion conglomeration accumulation and gathering, heat impediment swelling and pain, knocks and falls, heat entering construction-blood, vexation and agitation, insomnia and vexation, swelling toxin of welling abscess and sore, zoster, neurodermatitis, psoriasis. root

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000006 evodiamine l-Evodiamine; BDBM50366821; BB_NC-1930; ZINC00898159; Evodiamine, <i>Evodia rutaecarpa; evodiamine ; 518-17-2; CHEMBL486598; Evodiamine; ZINC2031813; C09187 C19H17N3O 303.36 CN1C2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3
TCMBANKIN000013 bufalin C24H34O4 386.5 g/mol CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O
TCMBANKIN000039 Zerumbone zerumbone; NSC698299; zerumbone ; 2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; AIDS051828; 2,6,10-Cycloundecatrien-1-one, 2,6,9,9-tetramethyl-, (E,E,E)-; (E,E,E)-2,6,9,9-Tetramethyl-2,6,10-cycloundecatrien-1-one; 471-05-6; (2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; AIDS-051828; (2E,6E,10E)-2,6,9,9-tetramethyl-1-cycloundeca-2,6,10-trienone; 2,6,9 humulatriene-8-one C15H22O 218.33 CC1=CCC(C=CC(=O)C(=CCC1)C)(C)C
TCMBANKIN000052 cannabidiol abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 C21H30O2 314.5 g/mol CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O
TCMBANKIN000064 diosgenin AKOS025402315; MolPort-028-744-580; (25R)-5-Spirosten-3beta-ol; 3beta-Hydroxy-5-spirostene; nitogenin; NSC 226132; Spirost-5-en-3-ol, (3beta,25S)-; diosgenin ; AC-8024; 512-04-9; 22-epi-Yamogenin; C08898; D1634_SIGMA C27H42O3 414.62 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1
TCMBANKIN000065 dioscin LMST01080053; C08897; 3-O-(Rhaa1-4(Rhaa1-2)Glcb)-(25R)-spirost-5-en-3beta-ol; dioscin ; 19057-60-4; Dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN000066 digitoxin C41H64O13 764.9 g/mol CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CCC7C8=CC(=O)OC8)O)C)C)C)C)O)O
TCMBANKIN000074 plumbagin plumbagin ; 5-hydroxy-2-methyl-1, 4-naphthoquinone C11H8O3 188.18 CC1=CC(=O)C2=C(C1=O)C=CC=C2O
TCMBANKIN000099 leonurine ST24030828; DTXSID70179434; CHEBI:80843; S-2878; Benzoic acid, 4-hydroxy-3,5-dimethoxy-, 4-[(aminoiminomethyl)amino]butyl ester; Ambotz24697-74-3; HY-N0741; MolPort-003-986-659; KS-000001AK; 7097-09-8; 4-carbamimidamidobutyl 4-hydroxy-3,5-dimethoxybenzoate; DS-1032; AC1L4PH9; 4-guanidinobutyl 4-hydroxy-3,5-dimethoxy-benzoate; ZINC5998954; 4-(diaminomethylideneamino)butyl 4-hydroxy-3,5-dimethoxybenzoate; 4-(diaminomethylideneamino)butyl 4-hydroxy-3,5-dimethoxy-benzoate hydrochloride; Leonurine-hydrochloride; FT-0659198; 697L743; CHEMBL1290284; AKOS025395615; N1392; CS-6071; 4-hydroxy-3,5-dimethoxybenzoic acid 4-guanidinobutyl ester; UNII-09Q5W34QDA; SC-45204; C16985; Benzoic acid, 4-hydroxy-3,5-dimethoxy-, 4-((aminoiminomethyl)amino)butyl ester; 09Q5W34QDA; SCM-198; VA11156; 4-(diaminomethylideneamino)butyl 4-hydroxy-3,5-dimethoxy-benzoate; MolPort-028-751-518; AN-3671; AB0023697; 4CH-009045; MFCD09839432; AK-39841; 4-Guanidino-n-butyl syringate; 7097/9/8; TL8002025; SCHEMBL2685302; BR-39841; 4-GUANIDINOBUTYL 4-HYDROXY-3,5-DIMETHOXYBENZOATE; Leonurine; 24697-74-3; W4810; Leonurine hydrochloride; AKOS015920020; 4-hydroxy-3,5-dimethoxy-benzoic acid 4-guanidinobutyl ester; D08KHD; AJ-64863 C14H21N3O5 311.33 COC1=CC(=CC(=C1O)OC)C(=O)OCCCCN=C(N)N
TCMBANKIN000114 theophylline C7H8N4O2 180.16 g/mol CN1C2=C(C(=O)N(C1=O)C)NC=N2
TCMBANKIN000705 Flavopiridol flavopiridol C21H20ClNO5 401.8 g/mol CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
TCMBANKIN002356 Mangostin CHEBI:67547; SR-05000002649; AC-6089; DivK1c_006670; KB-216381; NSC-139154; KBio1_001614; 6147-11-1; U6RIV93RU1; KBioGR_002529; CTK8C4814; ZINC5430812; KBio2_004774; SR-05000002649-1; BRD-K11991978-001-02-6; 1,3,6-Trihydroxy-7-methoxy-2,8-bis-(3-methyl-but-2-enyl)-xanthen-9-one; AIDS-180902; ANW-73224; alpha-Mangostin, >=98% (HPLC); NCGC00095730-03; NSC-30552; SC-86167; NSC27593; D06PRC; 2-methoxy-1,7-bis(3-methylbut-2-enyl)-3,6,8-tris(oxidanyl)xanthen-9-one; I14-4849; Mangostin, a-Mangostin; AN-10378; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthone; W2645; 6147/11/1; 9H-Xanthen-9-one,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; CS-6435; N2590; KS-00000LYA; NCGC00017251-04; AK105375; ACT09245; NCGC00178385-01; AC1NQYTD; KBioSS_002206; KBio3_002153; ZINC03925288; Q-100010; 1,3,6-Trihydroxy-7-methoxy-2,8-di(3-methyl-2-butenyl)xanthone; mangostin; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3,3-dimethylallyl)xanthone; DTXSID00210420; NCGC00095730-01; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)-9-xanthenone; AKOS015912806; CHEMBL323197; MolPort-001-736-566; 1,7-bis(3-methylbut-2-enyl)-3,6,8-trihydroxy-2-methoxyxanthen-9-one; SPBio_001659; 1,3,6-trihydroxy-7-methoxy-2,8-diprenylxanthone; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)- (9CI); NCGC00017251-05; DS-3359; Spectrum5_000622; SDCCGMLS-0066796.P001; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one; AK-693/21096021; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; NCGC00017251-03; BSPBio_002933; KBio2_002206; DB-053898; NCGC00017251-02; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; MFCD00135200; AIDS180902; TNP00140; C10080; N1590; SCHEMBL354735; SPECTRUM1505128; AJ-54080; BDBM50214969; AIDS-010791; AX8053706; Spectrum_001726; GNRIZKKCNOBBMO-UHFFFAOYSA-N; Xanthen-9-one,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)- (8CI); SpecPlus_000574; a-Mangostin; NSC30552; AIDS010791; CCG-36465; alpha-Mangostin; HY-N0328; D02ZPE; UNII-U6RIV93RU1; KBio2_007342; M2793; ST057241; NCGC00017251-01; NSC 27593; NSC 30552; 4-(4-Aminoethyl)Morpholine; Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; 147M111; NCGC00095730-02; FT-0635997; TR-021173; ST24036751; NSC-27593; Spectrum3_001297; HSDB 8103; Mangostine; NSC 139154; 4CN-1087; Spectrum4_001911; A833244; MCULE-1080742368; BIDD:ER0576; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)-9H-xanthen-9-one; Spectrum2_001620; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; SPECTRUM1504015; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-; NSC139154 C24H26O6 410.5 g/mol CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CC=C(C)C)O)C
TCMBANKIN005364 Phenylephrine C9H13NO2 167.2 g/mol CNCC(C1=CC(=CC=C1)O)O
TCMBANKIN012066 arundine C17H14N2 246.31 g/mol C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43
TCMBANKIN014187 seo-wenyujinacid B C2H6OS or HSCH2CH2OH C(CS)O
TCMBANKIN014683 Tobacco ene C9H6Cl6O3S C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl
TCMBANKIN016334 (-)-noradrenaline to_000024; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; KBio3_001579; CHEBI:18357; NCGC00159406-02; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Levoarterenol; KBio2_006625; KBio1_000230; L-Noradrenaline; NCGC00159406-05; Nor adrenalin (TN); Nor adrenalin; Noradrenaline (JP15); NINDS_000230; 4-[(1R)-2-amino-1-hydroxy-ethyl]pyrocatechol; Spectrum_001009; norepinephrinum; SPECTRUM1500436; KBio2_004057; Spectrum3_000520; KBio2_001489; DivK1c_000230; nchembio705-1; PDSP1_001111; 4-[(1R)-2-amino-1-hydroxy-ethyl]benzene-1,2-diol; 51-41-2; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; KBioSS_001489; C00547; NCGC00159406-04; BSPBio_002079; AIDS335520; A7257_SIGMA; KBioGR_000635; D00076; (&#8722;)-Norepinephrine; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; Spectrum5_001068; Arterenol; Spectrum4_000078; PDSP2_001095; Spectrum2_001064; (-)-(R)-Norepinephrine; SGCUT00123; AIDS-335520; Norepinephrine (INN); SPBio_001048; IDI1_000230 C8H11NO3 169.18 C1=CC(=C(C=C1C(CN)O)O)O
TCMBANKIN017939 α-lindane C6H6Cl6 or ClCH(CHCl)4CHCl C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
TCMBANKIN018273 sessilifoliamide B C17H27NO3 293.4 g/mol CCC(C1CCCCN2C1CCC2=O)C3CC(C(=O)O3)C
TCMBANKIN018789 eckol 88798-74-7; CHEMBL471187; 1-(3,5-Dihydroxyphenoxy)-2,4,7,9-tetrahydroxydibenzo-1,4-dioxin; 4-(3,5-dihydroxyphenoxy)-dibenzo(b,e)(1,4)dioxin-1,3,6,8-tetrol; D08MZY; Dibenzo[b,e][1,4]dioxin-1,3,6,8-tetrol, 4-(3,5-dihydroxyphenoxy)-; DTXSID40237333; ZINC6091359; 4-(3,5-dihydroxyphenoxy)oxanthrene-1,3,6,8-tetrol; AC1L3S7Z; BDBM50259982; CHEBI:65819; AIDS209851; Eckol; SCHEMBL2562621; Dibenzo(b,e)(1,4)-dioxin-1,3,6,8-tetrol, 4-(3,5-dihydroxyphenoxy)-; AIDS-209851; 4-(3,5-dihydroxyphenoxy)dibenzo-p-dioxin-1,3,6,8-tetrol C18H12O9 372.28 C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)O)O)O)O)O
TCMBANKIN021895 pectin (2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxy-2-tetrahydropyrancarboxylic acid; 14982-50-4; (2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid; GTR; C08348; Galacturonic acid; (2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid C6H10O7 194.14 C1(C(C(OC(C1O)O)C(=O)O)O)O
TCMBANKIN028288 morphine (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 C17H19NO3 285.34 CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
TCMBANKIN029312 melanin AKOS030232017; FT-0628190; 6,14-dimethyl-4,12-diazapentacyclo[8.6.1.1;{2,5}.0;{13,17}.0;{9,18}]octadeca-1(17),2,5,9(18),10,13-hexaene-7,8,15,16-tetrone; CHEBI:89634; D0WQ4G; API0003281; CTK8G0775; 8049-97-6; XUMBMVFBXHLACL-UHFFFAOYSA-N; Phaeomelanins; Melanin; 6,14-dimethyl-4,12-diazapentacyclo[8.6.1.1^{2,5}.0^{13,17}.0^{9,18}]octadeca-1(17),2,5,9(18),10,13-hexaene-7,8,15,16-tetrone; GTPL5415; Melanin from Sepia officinalis C18H10N2O4 318.3 g/mol CC1=C2C3=C(C4=CNC5=C(C(=O)C(=O)C(=C45)C3=CN2)C)C(=O)C1=O
TCMBANKIN031363 dimethyl sulfoxide C2H6OS 78.14 g/mol CS(=O)C
TCMBANKIN033678 caffeine NCGC00015208-02; DHCplus; KBio2_001781; W222402_ALDRICH; NINDS_000730; EINECS 200-362-1; Spectrum5_000423; BSPBio_001921; KBio1_000730; ACon1_000085; Probes1_000150; Quick-Pep; D00528; AIDS001649; WLN: T56 BN DN FNVNVJ B1 F1 H1; 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; SK 65 Compound; NCGC00090699-07; KBio2_006917; Stim; Caffeina [Italian]; 1,3,7-trimethylpurine-2,6-dione; PDSP2_001219; C7731_SIAL; KBioSS_001781; Caffein; Miudol; Nix Nap; nchembio774-comp2; Nodaca; Caffeine (natural); Cafeina; CFF; Caffeine solution; 7-methyltheophylline; 3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion (coffein); Bio1_000962; TNP00310; 75035_FLUKA; 1,3,7-Trimethyl-2,6-dioxopurine; NCGC00090699-08; Caffeine, anhydrous; Koffein [German]; C1778_SIAL; Dexitac; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; Durvitan; PDSP2_001000; MLS001066409; Eldiatric C; SPECTRUM1500155; cafeine; Koffein; NCIOpen2_008255; BRN 0017705; 71701-02-5; C8960_SIAL; Bio1_001451; MLS001056714; Caffeine (USP); caffenium; SPBio_001222; 27602_FLUKA; 95789-13-2; Spectrum3_000321; Cafecon; Thein; NCGC00015208-01; Coffeinum; 1-methyltheobromine; Mettler Toledo Calibration substance ME 18872, Caffeine; Kofein [Czech]; NSC 5036; Spectrum_001301; NCGC00090699-04; Bayer Select Headache Pain; Theine; Guaranine; KBio3_001141; NSC5036; 1,3,7-trimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine; Spectrum2_001261; EU-0100228; Probes2_000128; MEGxp0_001350; Anhydrous caffeine (TN); 1,3,7-Trimethylxanthine; 58-08-2; Caffedrine; C07481; No-Doz; PDSP1_001016; 3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion; InChI=1/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H; Phensal; Refresh'n; KBio2_004349; AIDS-001649; Tri-Aqua; Lopac0_000228; ZINC00001084; teina; Methyltheobromine; IDI1_000730; Caffeine, synthetic; 5-26-13-00558 (Beilstein); LS-187843; Theophylline Me; 5-26-13-00558 (Beilstein Handbook Reference); Coffein [German]; C6035_SIGMA; HSDB 36; DivK1c_000730; SDCCGMLS-0064595.P001; KBioGR_002325; NCI-C02733; SBB006474; Spectrum4_001782; Coffeine; Anhydrous caffeine; SMR000326667; 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-; Theobromine, 1-methyl-; Theophylline, 7-methyl; MolMap_000054; NCGC00090699-01; Theobromine Me; LS-237; Cafamil; Cafipel; c1094; AI3-20154; SDCCGMLS-0064595.P002; Xanthine, 1,3,7-trimethyl; Bio1_000473; Mateina; Methylxanthine theophylline; FEMA No. 2224; CHEBI:27732; Tirend; component of P-A-C Compound; Caffeine; Organex; NCGC00090699-03; component of Cafergot; CCRIS 1314; Methyltheobromide; Lopac-C-0750; 3,7-dihydro-1,3,7-trimethyl-1H-purine (9CI); Alert-Pep; C0750_SIAL; PDSP1_001235; Anhydrous caffeine (JP15); Vivarin; Caffeine [BAN:JAN]; Coffein; Caffine C8H10N4O2 194.19 CN1C=NC2=C1C(=O)N(C(=O)N2C)C
TCMBANKIN036791 Rocaglamide 505.6 g/mol
TCMBANKIN036802 ellagic acid 2,3,7,8-Tetrahydroxy(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione; 4,4',5,5',6,6'-hexahydroxydiphenic acid 2,6,2',6'-dilactone; CE0034; 5-19-07-00108 (Beilstein Handbook Reference); AS-12615; ellagic acid ; LTK-20; 133039-73-3; ellagicacid; NE58729; 2,3,7,8-Tetrahydroxy(1)benzopyrano(5,4,3-cde)-(1)benzopyran-5,10-dione; AIDS002688; Spectrum3_001535; SBB006501; 4,4&#8242;,5,5&#8242;,6,6&#8242;-Hexahydroxydiphenic acid 2,6,2&#8242;,6&#8242;-dilactone; Llagic acid; BRN 0047549; 2,6,2',6'-dilactone hydrate; 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; KBio2_004242; Polyphenolic; NCGC00094975-01; Eleagic acid; MFCD00149494; MolPort-000-705-556; 2,3,7,8-tetrahydroxy[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione; [1]Benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-; EINECS 207-508-3; NCGC00017245-01; NCI60_003869; Ellagsaeure; Ellagic Acid, Dihydrate; Diphenic acid, 4,4',5,5',6,6'-hexahydroxy-, di-.delta.-lactone; KBio3_002450; MLS-0066664.0001; KBio2_006810; SCHEMBL2639621; Ellagic acid hydrate, 97%, may cont. up to 12% water; Ellagic acid dihydrate; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0,(1).0(1)(1),(1)]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione dihydrate; Spectrum2_000905; Gallogen (astringent); TNP00132; KBioSS_001674; MLS000069632; SMP1_000111; (1)Benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-; BSPBio_002950; Oprea1_032884; C.I. 75270; NSC656272; SPBio_000750; NSC 656272; BCBcMAP01_000154; Elagostasine; I14-61927; NSC 407286; BB_NC-0491; C10788; C.I. 55005; 2,3,7,8-Tetrahydroxy[1]benzopyrano-[5,4,3-cde][1]benzopyran-5,10-dione; Spectrum_001194; Gallogen, astringent; SMR000058244; CHEBI:4775; SPECTRUM1502245; KBio2_001674; KBioGR_001080; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0^{4,16}.0^{11,15}]hexadeca-1(15),4(16),5,7,11,13-hexaene-3,10-dione dihydrate; Acido elagico [INN-Spanish]; BG00667714; 476-66-4; Benzoaric acid; AK186482; SDCCGMLS-0066664.P001; Z1551861526; CCRIS 774; Gallogen (VAN); NSC407286; Ellagic acid [DCF:INN]; [1,1'-Biphenyl]-2,2'-dicarboxylic acid, 4,4',5,5',6,6'-hexahydroxy-, di-.delta.-lactone; CCG-208140; NCGC00094975-02; 4,4&prime;,5,5&prime;,6,6&prime;-Hexahydroxydiphenic Acid 2,6,2&prime;,6&prime;-Dilactone; Spectrum4_000750; Alizarine Yellow; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0?,??.0??,??]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione dihydrate; Diphenic acid, 4,4',5,5',6,6'-hexahydroxy-, di-delta-lactone; AIDS-002688; AKOS025310087; Acidum ellagicum [INN-Latin]; Lagistase; ZINC00058174; C14H6O8.2H2O; Spectrum5_000959; E2250_SIGMA; Acide ellagique [INN-French]; NCGC00094975-03; 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione dihydrate; Ellagic acid C14H6O8 302.193 c1(O[H])c([H])c2c(c(c(C(=O)O3)c([H])c(O[H])c4O[H])c4OC2=O)c3c1O[H]
TCMBANKIN036810 Butein 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 2&prime;,4&prime;,3,4-Tetrahydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-; NCGC00163519-01; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; NSC652892; AIDS057944; AC1NST6X; AIDS-057944; 3,4,2',4'-Tetrahydroxychalcone; ST5331397; 2',3,4,4'-Tetrahydrochalcone; 2',3,4,4'-Tetrahydroxychalcone; B178_SIGMA; butein ; MolMap_000005; Chalcone, 2',3,4,4'-tetrahydroxy- (7CI,8CI); EINECS 207-659-5; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-; C08578; butein; 2',4',3,4-Tetrahydroxychalcone; 2&#8242;,3,4,4&#8242;-Tetrahydroxychalcone; Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihydroxyphenyl)-; NCI60_018489; HSCI1_000162; 21849-70-7; (Z)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 487-52-5; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one C15H12O5 272.25 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O
TCMBANKIN036813 Bilobalide 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; AIDS-029698; AIDS029698; NCGC00142501-01; 33570-04-6; bilobalide; SMR000232342; ST057155; 4H,5aH,9H-Furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-,(3aS,5aR,8R,8aS,9R,10aS)-; NCGC00142501-02; MLS000563448 C15H18O8 326.3 CC(C)(C)C1(CC2C3(C14C(C(=O)OC4OC3=O)O)CC(=O)O2)O
TCMBANKIN036846 Icariin 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-chromen-4-one; MLS000759413; Spectrum4_001975; ZINC03960893; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy-chromen-4-one; Spectrum2_001695; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-3-[[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-2-tetrahydropyranyl]oxy]-4-chromenone; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-chromone; Spectrum3_001130; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one; 489-32-7; 2-(4'-methoxyl phenyl)-3-rhamnosido-5-hydroxyl-7-glucosido-8-(3'-methyl-2-butylenyl)-4-chromanone; SPBio_001650; SPECTRUM1505257; KBio3_002099; KBioGR_002475; SDCCGMLS-0066754.P001; SMR000466309; BB_NC-0999; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Spectrum5_000933; icariin; BSPBio_002599; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(beta-D-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; ICA C33H40O15 677 O1[C@@]([H])(Oc2c(C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])c(OC(c3c([H])c([H])c(OC([H])([H])[H])c([H])c3[H])=C(O[C@@]4([H])[C@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(C([H])([H ])[H])O4)C5=O)c5c(O[H])c2[H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]1([H])C([H])([H])O[H]
TCMBANKIN036848 triptolide PG 490; CT0223; Bio2_000315; AKOS015895128; KBio2_005451; BSPBio_001595; NCGC00163411-02; Triptolide; BCPP000033; Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS*,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS*,8b.beta.)]-; KBio3_000629; N1733; CHEBI:94966; SCHEMBL10028421; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; AC-6084; IDI1_034065; NCGC00163411-01; NSC163062; KBio2_002883; NSC 163062; Bio2_000795; Triptolid; HY-32735; BRD-A13122391-001-01-9; SMR000466307; MLS000759410; Triptolide (9CI); C09204; Triptolide, <i>Tripterygium wilfordii; PG-490; ST51052768; KBio2_000315; Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS*,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS*,8b.beta.)]-; CS-0286; KBio3_000630; Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid; 38748-32-2; PG490; SMP1_000110; KBioGR_000315; TPL; NCI60_001223; KBioSS_000315 C20H24O6 360.4 CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C
TCMBANKIN036864 Gymnasterkoreayne B 258.35 g/mol
TCMBANKIN036885 protopanaxadiol C30H52O3 460.7 g/mol CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)O)C)C)O)C)O)C
TCMBANKIN036894 scutellarin (2S,3S,4S,5R,6S)-6-[[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-7-chromenyl]oxy]-3,4,5-trihydroxy-2-tetrahydropyrancarboxylic acid; CHEBI:61284; 676536-34-8; 1329-06-2; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-; Flavone, 4',5,6,7-tetrahydroxy-, 7-beta-D-glucopyranuronoside; scutellarin(1-); scutellarein 7-O-beta-D-glucuronate; Scutellarein-7beta-D-glucuronide; AIDS-314104; AIDS314104; 32647-60-2; Scutellarein-7-O-beta-D-glucuronide; Scutellarein-7-glucuronide; Breviscapine; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; 116122-36-2; Breviscapin; MEGxp0_000554; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl; Glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, beta-D-; Scutellarin; Scutellarein-7beta-D-glucuronoside; 27740-01-8; 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranosiduronate; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-keto-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid C21H18O12 462.4 g/mol C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O
TCMBANKIN037813 genistein BSPBio_002375; Lopac-G-6649; NCGC00015479-02; K00046; Genisteol; Spectrum_000320; NCGC00025005-01; Sophoricol; KBio2_003368; 4,6,7-Trihydroxyisoflavone; SMR000112580; SIPI 807-1; KBio2_007700; 5,7,4'-Trihydroxyisoflavone; Spectrum4_001543; GEN; NCGC00025005-04; Lopac0_000520; AIDS097204; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; Spectrum5_000106; Bio1_001423; NCGC00025005-05; NSC 36586; NCGC00025005-02; 4&prime;,5,7-Trihydroxyisoflavone; Differenol A; NPI 031L; ACon1_001065; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; Bio1_000934; NCI60_003369; UPCMLD-DP096:001; NCGC00015479-01; genistein ; Spectrum2_000638; KBio2_002564; nchembio.76-comp6; G6776_SIGMA; DivK1c_006401; 5-18-04-00594 (Beilstein Handbook Reference); cMAP_000086; EU-0100520; 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate; Tocris-1110; CHEBI:74224; KBioGR_002006; Bio1_000445; BRN 0263823; 446-72-0; MEGxp0_000568; Oprea1_437815; SMP1_000133; KBio1_001345; 5,7-DIHYDROXY-3-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; Lactoferrin-genistein; SPECTRUM210296; 4',5, 7-trihydroxyisoflavone; NSC36586; EINECS 207-174-9; CHEBI:28088; Oprea1_224620; AIDS-097204; 4',5,7-Trihydroxyisoflavone; C06563; KBio3_003042; SPBio_000636; genistein(1-); KBio2_000800; 4&#8242;,5,7-Trihydroxyisoflavone; G6649_SIGMA; Prunetol; KBioGR_002564; C.I. 75610; KBioSS_000800; Genistein; TNP00151; CCRIS 7675; MolMap_000022; KBio2_005132; KBio3_001595; ZINC00041692; AIDS016499; ST056352; SpecPlus_000305; Isoflavone, 4',5,7-trihydroxy-; 4',5,7-Trihydroxy isoflavone; STO514; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; KBioSS_002573; KBio2_005936; Genistein; 4',5,7-Trihydroxyisoflavone; Spectrum3_000678; PTI G4660; AIDS-016499; nchembio.2007.28-comp32; Genisterin; NCGC00025005-07; MLS000738127 C15H10O5 270.24 C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
TCMBANKIN042858 Luteolin Prestwick3_000870; TNP00073; 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-olate luteolin-7-olate(1-); 62696_FLUKA; ACon1_000223; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromenone; Digitoflavone; SMR000326896; luteolin-7-olate anion; 4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; CHEBI:57545; FLAVONE, 3',4',5,7-TETRAHYDROXY-; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone; A827664; BPBio1_001011; MEGxp0_000143; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI); Weld Lake; BSPBio_000919; CHEBI:15864; 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-olate; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one; Oprea1_849964; Yama kariyasu; 4-[5,7-bis(oxidanyl)-4-oxidanylidene-chromen-2-yl]-2-oxidanyl-phenolate; ST024703; luteolin ; NCGC00016467-02; EINECS 207-741-0; AIDS001406; NCGC00142375-02; C.I. Natural Yellow 2; S00110; Luteoline; Luteolin; Luteolol; 3&prime;,4&prime;,5,7-Tetrahydroxyflavone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; Prestwick_122; 5,7,3',4'-Tetrahydroxyflavone; BRN 0292084; CAS-491-70-3; 4-(5,7-dihydroxy-4-oxo-1-benzopyran-2-yl)-2-hydroxyphenolate; ZINC00008613; NCGC00142375-01; Prestwick1_000870; AIDS-001406; C01514; CCRIS 3790; 3',4',5,7-Tetrahydroxyflavone; Flacitran; Cyanidenon 1470; MLS000697655; SPBio_002840; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Lopac0_000660; NCGC00016467-01; C.I. 75590; Prestwick0_000870; 491-70-3; 2-(3,4-Dihydroxyphenyl)-5-hydroxy-7-oxylato-4H-1-benzopyran-4-one; 5-18-05-00296 (Beilstein Handbook Reference); Prestwick2_000870; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; L9283_SIGMA; 3&#8242;,4&#8242;,5,7-Tetrahydroxyflavone; SMP2_000042; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromone C15H10O6 286.236 c1(O[H])c([H])c(OC(c2c([H])c([H])c(O[H])c(O[H])c2[H])=C([H])C3=O)c3c(O[H])c1[H]
TCMBANKIN042919 vaticanol c C56H42O12 906.9 g/mol C1=CC(=CC=C1C2C3C(C4=C(C2C5=C3C6=C(C=C5O)OC(C6C7=CC(=CC(=C7)O)O)C8=CC=C(C=C8)O)C9=C(C=C4O)OC(C9C1=CC(=CC(=C1)O)O)C1=CC=C(C=C1)O)C1=CC=C(C=C1)O)O
TCMBANKIN044183 irisolidone 5,7-dihydroxy-6-methoxy-3-(4-methoxyphenyl)-4-chromenone; Irisolidone; 5,7-dihydroxy-6-methoxy-3-(4-methoxyphenyl)chromone; 2345-17-7; C10471; 5,7-dihydroxy-6-methoxy-3-(4-methoxyphenyl)chromen-4-one C17H14O6 314.29 COC1=CC=C(C=C1)C2=COC3=C(C2=O)C(=C(C(=C3)O)OC)O
TCMBANKIN057899 arsenicum;arsenic;as As 74.92159 g/mol [As]
TCMBANKIN057911 se selenium H2Se 78.97 g/mol [Se]
TCMBANKIN057919 2(R)-(3,4-dimethoxy-phenyl)-propanel,3-diol-l-O-β-D-glucopyranoside formic acid;fatty acids;FMT;saturated fatty acids;formicacid; methanol peroxide; Dioxirane-3-ol;251364_SIAL; 64-18-6; 27001_RIEDEL; HCOOH; Kyselina mravenci [Czech]; methoic acid; 06473_FLUKA; Spirit of formic acid; Formira; CBX; RCRA waste no. U123; Formylic acid; Methanoic acid; 09676_FLUKA; Formic acid (natural); C1 acid; CCRIS 6039; 49897_FLUKA; 7056-83-9; Kwas metaniowy [Polish]; Bilorin; Myrmicyl; RCRA waste number U123; Ameisensaeure [German]; F0507_SIAL; Collo-didax; EINECS 200-579-1; UN1779; C00058; Add-F; InChI=1/CH2O2/c2-1-3/h1H,(H,2,3; 33015_RIEDEL; 82069-14-5; H-COOH; Collo-bueglatt; LMFA01010040; 94318_FLUKA; AI3-24237; Wonderbond Hardener M 600L; HSDB 1646; Mierenzuur [Dutch]; formic acid; 06450_FLUKA; Sybest; Formic acid solution; FEMA No. 2487; Formisoton; CHEBI:30751; Ameisensaeure; 399388_SIAL; ST5214364; 8006-93-7; Ameisensaure; Formate standard for IC; CARBOXY GROUP; LS-1540; Methanoic acid monomer; Formic acid [UN1779] [Corrosive]; W248703_ALDRICH; Acide formique [French]; Aminic acid; Acido formico [Italian]; 06460_FLUKA; 15907-03-6; Hydrogen carboxylic acid; EPA Pesticide Chemical Code 214900; 56302_FLUKA HCOOH or CH2O2 46.025 g/mol;46.03 C(=O)O
TCMBANKIN058050 Oil garlic; allyl monosulfide; diallyl sulfide Diallyl sulphide; BSPBio_003591; Spectrum2_000837; NSC 20947; Thioallyl ether; 3-(allylthio)prop-1-ene; SPBio_000793; 3,3'-thiobis(prop-1-ene); 32660_FLUKA; WLN: 1U2S2U1; Dially monosulfide; SPECTRUM1505293; Diallyl thioather; Allyl sulfide; KBio3_003027; Diallyl monosulfide; NSC20947; A35801_ALDRICH; Allyl monosulfide; AI3-18865; Spectrum3_001991; 592-88-1; Diallyl sulfide; InChI=1/C6H10S/c1-3-5-7-6-4-2/h3-4H,1-2,5-6H; 4-01-00-02097 (Beilstein Handbook Reference); 3-prop-2-enylsulfanylprop-1-ene; W204218_ALDRICH; 2-Propenyl sulphide; EINECS 209-775-1; LS-16414; ZINC01531083; 1-Propene, 3,3'-thiobis-; 3-allylsulfanylprop-1-ene; FEMA No. 2042; C08370; CCRIS 3252; SDCCGMLS-0066835.P001; AIDS-109731; BRN 1736016; Diallyl thioether; AIDS109731; 3,3-Thiobis(1-propene); 132879-26-6; NCGC00095345-01; CC-26436; BSPBio_003591; A0235; Q-100687; diallylsulfide; 3,3'-Thiobis-1-propene, 9CI; KB-49700; KBio3_003027; Diallyl monosulfide; ACMC-209mc0; Allyl monosulfide; KSC490I9L; ST51046353; (CH2=CHCH2)2S; di-2-Propenyl sulfide; 3-prop-2-enylsulfanylprop-1-ene; CJ-24086; FEMA No. 2042; C08370; CCRIS 3252; SDCCGMLS-0066835.P001; Diallyl thioether; 132879-26-6; 4-Thia-1,6-heptadiene; SCHEMBL45800; Spectrum2_000837; NSC 20947; 3,3'-thiobis(prop-1-ene); Allyl sulfide, United States Pharmacopeia (USP) Reference Standard; SPECTRUM1505293; SBB060116; SR-05000002373; NSC-20947; AC1L1XQU; AI3-18865; MFCD00008658; 592-88-1; HSDB 7333; BDBM50318452; 1-Propene, 3,3'-thiobis-; 3-allylsulfanylprop-1-ene; RP19166; 7490AF; TRA0077955; FCH1115787; UNII-60G7CF7CWZ; NCGC00095345-01; DIALLYL SULFIDE; Allyl sulphide; Diallyl sulphide; TC-020290; DTXSID6060470; paragraph signthornI(c)+/-u>>uAoAN; 1-Propene,3,3'-thiobis-; SPBio_000793; 3-Allylsulfanyl-propene; NCGC00095345-02; 1-prop-2-enylthioprop-2-ene; Prop-1-ene-3,3'-thiobis; AKOS015897442; AN-46219; 3-(Allylsulfanyl)-1-propene; MCULE-7417537491; Spectrum3_001991; InChI=1/C6H10S/c1-3-5-7-6-4-2/h3-4H,1-2,5-6H; 4-01-00-02097 (Beilstein Handbook Reference); RTC-020290; 2-Propenyl sulphide; EINECS 209-775-1; ZINC1531083; KS-00000X7D; CTK3J0495; MolPort-003-665-654; I09-0131; 3-(prop-2-en-1-ylsulfanyl)prop-1-ene; CCG-40295; DB-053358; FEMA 2042; Thioallyl ether; C-27437; WLN: 1U2S2U1; Dially monosulfide; Diallyl thioather; Allyl sulfide; 3-(Allylsulfanyl)-1-propene #; Allyl sulfide, 97%; Allyl sulfide, analytical standard; NSC20947; Allyl sulfide, >=97%, FG; STL453662; 60G7CF7CWZ; 1-Propene,3'-thiobis-; LS-16414; UBJVUCKUDDKUJF-UHFFFAOYSA-N; CHEBI:4489; ANW-33214; CHEMBL170458; C6H10S; SR-05000002373-1; CJ-05229; BRN 1736016; Oil garlic; 3,3-Thiobis(1-propene); FT-0624605 C6H10S 114.21 g/mol C=CCSCC=C
TCMBANKIN058052 diAllS2 3-prop-2-enyldisulfanylprop-1-ene; NSC 29228; Di(2-propenyl) disulfide; W202800_ALDRICH; Allyl disulphide; 3,3'-dithiobis(prop-1-ene); NCI60_002410; ZINC01531082; AI3-35128; SPECTRUM1505174; HSDB 595; 3-(prop-2-en-1-yldisulfanyl)prop-1-ene; 2179-57-9; Allyl disulfide; AIDS-005092; BRN 1699241; Diallyl disulphide; NCGC00095294-01; NSC29228; CHEBI:4488; Disulfide, di-2-propenyl; AIDS005092; C08369; 317691_ALDRICH; 3-allyldisulfanylprop-1-ene; 2-Propenyl disulfide; 3,3'-disulfanediylbis(prop-1-ene); 3-(allyldisulfanyl)-1-propene; 4,5-Dithia-1,7-octadiene; 4-01-00-02098 (Beilstein Handbook Reference); FEMA No. 2028; NCGC00095294-02; EINECS 218-548-6; 32621_FLUKA; CCRIS 6290; Diallyl disulfide; 2-Propenyl disulphide;allyl disulfide;diallyldisulfide;CAS-2179-57-9; DSSTox_RID_79248; CCG-214421; NCI60_002410; C-27435; Jsp004430; AI3-35128; HSDB 595; di-Propenyl disulfide; Allyl disulfide; 3-(prop-2-en-1-yldisulfanyl)prop-1-ene; SPECTRUM1505174; ZINC1531082; LS-16413; NCGC00095294-01; DTXSID9035206; TC-040016; UNII-609MRV3T0J component PFRGXCVKLLPLIP-UHFFFAOYSA-N; CHEBI:4488; SCHEMBL93944; MolPort-003-665-653; SR-05000002379; MFCD00008656; Garlicin?; DSSTox_CID_15206; CJ-24085; NSC-29228; Disulfide,di-2-propenyl; TRA0072391; FCH1114751; 2-Propenyl disulphide; Di(2-propenyl) disulfide; 3-(Allyldisulfanyl)-1-propene; 3-Allyldisulfanyl-Propene; Allyl disulfide, United States Pharmacopeia (USP) Reference Standard; AN-20744; FEMA 2028; diAllS2; CTK3J1568; CHEMBL366603; J-014293; Allitin; ACMC-1CDL1; Allyl disulfide, >=80%, FG; BDBM50318453; AC1L28A0; Disulfide, di-2-propen-1-yl; 1,2-Diallyldisulfane; A815665; FEMA No. 2028; 7491AF; NCGC00095294-02; API0002303; AKOS015840490; AK307043; ANW-24581; 3-(prop-2-enyldisulfanyl)prop-1-ene; 5HI47O6OA7; NSC 29228; DB-003623; Allyl disulphide; diprop-2-enyl disulfide; CJ-05228; 3,3'-dithiobis(prop-1-ene); Allyl disulfide, technical grade, 80%; DIALLYL DISULFIDE; 2179-57-9; Diallyldisulfide; ST51038174; KS-00000V5X; 3-(Allyldisulfanyl)-1-propene #; Diallyl disulfide, analytical standard; C6H10S2; 2-Propenyl disulfide; 4,5-Dithia-1,7-octadiene; D0071; EINECS 218-548-6; Diallyl disulfide, >=98% (HPLC); CCRIS 6290; PFRGXCVKLLPLIP-UHFFFAOYSA-N; Tox21_302178; MCULE-7486690483; UNII-5HI47O6OA7; 3-(allyldisulfanyl)prop-1-ene; Di-2-propenyl disulfide, 9CI; I09-0165; RTC-040016; KSC491K6R; NCGC00255533-01; BRN 1699241; Diallyl disulphide; NSC29228; DSSTox_GSID_35206; Disulfide, di-2-propenyl; CC-26440; C08369; 3,3'-disulfanediylbis(prop-1-ene); SC-77190; di-2-Propenyl disulfide; diallyldisulphide; 3-(prop-2-enyldisulfanyl)-1-propene; AC1Q7EA7; FT-0624594; SR-05000002379-1;diallyl disulfide ; diallyl disulfide C6H10S2 146.27 C=CCSSCC=C
TCMBANKIN058053 diallyl trisulfide DSSTox_CID_25972; SCHEMBL562845; CHEMBL123040; 3-(prop-2-enyltrisulfanyl)-1-propene; Trisulfide,di-2-propen-1-yl; Prop-2-enyl-trithio prop-2-ene; 1,3-Diallyltrisulfane; DSSTox_GSID_45972; 4,5,6-Trithia-1,8-nonadiene; Allyl trisulfide, 8CI; FEMA 3265; MolPort-003-665-652; DTXSID9045972; 050D875; Allitridin; 2050-87-5; Trisulfide, di-2-propenyl (9CI); NSC651936; allitridin; diallylTrisulfide; A814621; Diallyl trisulfide, >=98% (HPLC); EINECS 218-107-8; BDBM50318454; 8008-99-9; AI3-35127; C6H10S3; RT-003641; Diallyltrisulfide; CJ-26310; diallyltrisulfane; CTK3J7216; 1,3-Diallyltrisulfane #; CCG-230978; CCRIS 3251; C-51303; KS-00000ZOW; M259; bis(prop-2-en-1-yl)trisulfane; Tox21_111500; AC1L27PI; Garlic oil; BRN 1745734; Jsp004197; FT-0626632; Diallyl trisulphide; allitridum; FT-0624607; SPECTRUM1505014; 0-01-00-00441 (Beilstein Handbook Reference); (CH2=CHCH2S)2S; DSSTox_RID_81264; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Diallyl trisulfide, >=97% (HPLC); AKOS006282485; ALLYL TRISULFIDE; UNII-609MRV3T0J component UBAXRAHSPKWNCX-UHFFFAOYSA-N; 3-(allyltrisulfanyl)prop-1-ene; Q-100252; CAS-2050-87-5; DB-003624; CHEBI:78492; Dasuansu; NCGC00095290-01; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-02; AB1006016; KB-49701; FEMA No. 3265; NSC 651936; Diprop-2-en-1-yltrisulfane; diallyl trisulfide ; 0ZO1U5A3XX; NSC-651936; BC216501; UNII-0ZO1U5A3XX; I09-0167; Trisulfide, di-2-propenyl; Diallyl trisulfide; AN-19812; Di-2-propenyl trisulfide; FCH834827; 1,3-Diallyltrisulfane; LS-2660; 3-(prop-2-enyltrisulfanyl)prop-1-ene; DSSTox_CID_25972; SCHEMBL562845; CHEMBL123040; 3-(prop-2-enyltrisulfanyl)-1-propene; Trisulfide,di-2-propen-1-yl; Prop-2-enyl-trithio prop-2-ene; 1,3-Diallyltrisulfane; DSSTox_GSID_45972; 4,5,6-Trithia-1,8-nonadiene; Allyl trisulfide, 8CI; FEMA 3265; MolPort-003-665-652; AIDS008801; DTXSID9045972; 050D875; Allitridin; 2050-87-5; 3-prop-2-enylsulfanyldisulfanylprop-1-ene; Trisulfide, di-2-propenyl (9CI); AIDS-008801; NSC651936; A814621; Diallyl trisulfide, >=98% (HPLC); EINECS 218-107-8; BDBM50318454; 8008-99-9; AI3-35127; C6H10S3; RT-003641; Diallyltrisulfide; CJ-26310; diallyltrisulfane; CTK3J7216; 1,3-Diallyltrisulfane #; CCG-230978; CCRIS 3251; C-51303; KS-00000ZOW; M259; bis(prop-2-en-1-yl)trisulfane; Tox21_111500; AC1L27PI; Garlic oil; BRN 1745734; Jsp004197; FT-0626632; Diallyl trisulphide; allitridum; FT-0624607; SPECTRUM1505014; 0-01-00-00441 (Beilstein Handbook Reference); (CH2=CHCH2S)2S; DSSTox_RID_81264; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Diallyl trisulfide, >=97% (HPLC); AKOS006282485; ALLYL TRISULFIDE; UNII-609MRV3T0J component UBAXRAHSPKWNCX-UHFFFAOYSA-N; 3-(allyltrisulfanyl)prop-1-ene; Q-100252; CAS-2050-87-5; DB-003624; CHEBI:78492; Dasuansu; NCGC00095290-01; 3-allylsulfanyldisulfanylprop-1-ene; FEMA No. 3533; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-02; AB1006016; 3-(allylthio)disulfanylprop-1-ene; KB-49701; FEMA No. 3265; NSC 651936; Diprop-2-en-1-yltrisulfane; 0ZO1U5A3XX; NSC-651936; BC216501; UNII-0ZO1U5A3XX; I09-0167; Trisulfide, di-2-propenyl; Diallyl trisulfide; AN-19812; Di-2-propenyl trisulfide; FCH834827; 1,3-Diallyltrisulfane; LS-2660; 3-(prop-2-enyltrisulfanyl)prop-1-ene; allitridin C6H10S3 178.34 C=CCSSSCC=C
TCMBANKIN058060 gallic acid Spectrum4_001544; NSC-755825; 4CN-0954; KBio2_000822; NCGC00260064-01; KBio3_001168; CHEBI:30778; GTPL5549; D0Y3TZ; NCGC00091125-01; 632XD903SP; ARONIS23903; Spectrum5_000108; Jsp002851; T7419; Gallic acid, puriss., 98.0%; I14-9302; NCGC00091125-07; ZINC1504; 3,4,5-trihydroxybenzoic acid (ACD/Name 4.0); KBioGR_002008; AK-65266; pyrogallol-5-carboxylate; BRD-K77345217-001-01-9; Gallicum acidum; LNTHITQWFMADLM-UHFFFAOYSA-N; KBio2_003390; EBD679760; NCGC00091125-04; AJ-08037; Gallic acid; ZB000350; BG01502846; A808977; (?)-Gallic acid; WLN: QVR CQ DQ EQ; N1830; AC1NEVA5; SBB008781; 149-91-7; GALLIC ACID ANHYDROUS; Gallic acid [NF]; KS-00000IWM; CS-8191; LS-870; C01424; KS-00004784; CHEBI:16918; SPECTRUM210369; c0006; UNII-632XD903SP; ACMC-20aku5; CTK0H5618; BIDD:ER0374; AC1Q732X; NCGC00091125-02; F1908-0156; Oprea1_087792; CG0029; DSSTox_RID_75711; Kyselina 3,4,5-trihydroxybenzoova; 3-10-00-02070 (Beilstein Handbook Reference); RP23206; NSC36997; Gallic acid, certified reference material, TraceCERT(R); AI3-16412; CCG-38670; STK298718; Tox21_202515; bmse000389; AN-15162; AB00052697_03; SR-05000001537-2; NSC-36997; 1886-EP2374526A1; 5-Carboxybenzene-1,2,3-triol; KBio2_005958; SR-05000001537-3; NCGC00091125-05; KBio1_001347; Kyselina gallova [Czech]; KSC175M1R; KBioSS_000822; HMS2091A07; gallate; CPD-183; Spectrum3_000254; 78563C7D-0E2D-4766-A8EA-670A03C78FCF; gallic acid ; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; GDE; SBI-0052184.P002; EINECS 205-749-9; CAS-149-91-7; Kyselina gallova; J3.617.291F; Benzoic acid, 3,4,5-trihydroxy-; BG00601456; DivK1c_006403; Benzoic acid,4,5-trihydroxy-; gallic acid for microelectronic industrial; BRN 2050274; Gallic acid tech.; NCGC00091125-03; Kyselina 3,4,5-trihydroxybenzoova [Czech]; Gallic acid, 97.5-102.5% (titration); gallicacid; 3,4,5-Trihydroxybenzoic acid, anhydrous; NSC674319; TR-020762; 3,4,5-tris(oxidanyl)benzoate; MCULE-1552954312; Gallic acid polymer; Pharmakon1600-00210369; BSPBio_001668; Tox21_111089; HMS1923K07; CCRIS 5523; BDBM50085536; NSC-674319; ST2404570; BB_SC-2795; AC-1206; 3,4,5-trihydroxy-Benzoic acid; Gallic Acid Hydrate; AC1L1934; RTR-020762; GALOP; Q-201146; SR-05000001537-1; DSSTox_CID_650; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; 3,4,5-Trihydroxybenzoic acid ion; GALLICACID; s4603; CHEMBL288114; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; NSC755825; G0011; AB1002218; Gallic Acid, F; MolPort-000-881-260; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; PS-8710; SC-46383; FT-0626592; BBL009937; MFCD00002510; SpecPlus_000307; 3,4,5-trihydroxy-Benzoate; SCHEMBL15012; DSSTox_GSID_20650; ST083487; SR-05000001537; 3,5-Trihydroxybenzoic acid; 3,4,5-Trihydroxybenzoate, X; Tox21_111089_1; Gallic acid (Monohydrate or Anhydrous) (3,4,5-Trih; 3,4,5-Trihydroxybenzoic acid;; Z966690556; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; BC200279; Spectrum2_000399; HY-N0523; HSDB 2117; AC1Q732Y; DTXSID0020650; 5-Trihydroxybenzoic acid; AKOS000119625; NSC 20103; Gallic acid, tech; 138-57-8; NSC-20103; AIDS-001349; gallate; CPD-183; Spectrum3_000254; KBio2_000822; Gallic acid monohydrate; AIDS-059239; KBio3_001168; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; C01424; CHEBI:30778; EINECS 205-749-9; CHEBI:16918; NCGC00091125-01; c0006; J3.617.291F; SPECTRUM210369; Benzoic acid, 3,4,5-trihydroxy-; DivK1c_006403; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; Spectrum5_000108; NCGC00091125-02; BRN 2050274; Oprea1_087792; NCGC00091125-03; 3-10-00-02070 (Beilstein Handbook Reference); SpecPlus_000307; Kyselina 3,4,5-trihydroxybenzoova [Czech]; KBioGR_002008; AI3-16412; NSC674319; pyrogallol-5-carboxylate; 3,4,5-tris(oxidanyl)benzoate; AIDS001349; KBio2_003390; Gallic acid polymer; 1886-EP2374526A1; ZB000350; Gallic acid; BSPBio_001668; KBio2_005958; AIDS059239; CCRIS 5523; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; A808977; 27645_RIEDEL; KBio1_001347; 398225_SIAL; Kyselina gallova [Czech]; WLN: QVR CQ DQ EQ; Spectrum2_000399; HSDB 2117; G7384_SIGMA; KBioSS_000822; GALOP; AC1NEVA5; SBB008781; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; NSC 20103; 3,4,5-Trihydroxybenzoic acid ion; 149-91-7; 3,4,5-trihydroxybenzoic acid; Galllic acid C7H6O5 170.12 C1=C(C=C(C(=C1O)O)O)C(=O)O
TCMBANKIN058113 Butein 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 2&prime;,4&prime;,3,4-Tetrahydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-; NCGC00163519-01; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; NSC652892; AIDS057944; AC1NST6X; AIDS-057944; 3,4,2',4'-Tetrahydroxychalcone; ST5331397; 2',3,4,4'-Tetrahydrochalcone; 2',3,4,4'-Tetrahydroxychalcone; B178_SIGMA; butein ; MolMap_000005; Chalcone, 2',3,4,4'-tetrahydroxy- (7CI,8CI); EINECS 207-659-5; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-; C08578; butein; 2',4',3,4-Tetrahydroxychalcone; 2&#8242;,3,4,4&#8242;-Tetrahydroxychalcone; Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihydroxyphenyl)-; NCI60_018489; HSCI1_000162; 21849-70-7; (Z)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 487-52-5; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one C15H12O5 272.25 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O
TCMBANKIN058140 fisetin Spectrum4_001070; BSPBio_002952; ST057233; C.I. 75620; NSC407010; Superfustel K; Viset; ZINC00039111; CHEBI:42567; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromone; NCI60_003865; Fisetin; Fietin; KBio1_001500; TNP00004; 2-(3,4-DIHYDROXYPHENYL)-3,7-DIHYDROXY-4H-CHROMEN-4-ONE; 5-Desoxyquercetin; Fisetin; 5-Deoxyquercetin; 3,3?,4?,7-Tetra??hydroxy??flavone; Natural Brown 1; 3,7-Dihydroxy-2-(3,4-dihydroxyphenyl)-4H-1-benzopyran-4-one; SPECTRUM1502247; NSC 656275; NCIMech_000006; C10041; Ventin sumach; AIDS-003057; NCGC00017344-02; 3,3',4',7-Tetrahydroxyflavone; KBio2_006812; Spectrum3_001536; KBio2_004244; SDCCGMLS-0066657.P001; SPBio_001119; Spectrum2_001160; Spectrum5_001797; 3,7,3',4'-TETRAHYDROXYFLAVONE; DivK1c_006556; 5-18-05-00291 (Beilstein Handbook Reference); Superfustel; EINECS 208-434-4; SpecPlus_000460; Cotinin; 528-48-3; NCGC00017344-01; Young fustic; KBioGR_001400; S00056; NSC656275; AIDS003057; KBioSS_001676; Bois bleu de Honqrie; FLAVONE, 3,3',4',7-TETRAHYDROXY-; Young fustic crystals; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4-chromenone; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one; Spectrum_001196; Fustel; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-; TNP00284; C.I. Natural Brown 1; Ungarisches gelbholz; NCGC00095663-02; Junger fustik; fisetin ; KBio2_001676; 7,3',4'-Trihydroxyflavonol; KBio3_002452; BOIS bleude honqrie; NCGC00095663-01; InChI=1/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20; BRN 0292829; Fisetholz; CHEBI:71992; Fustet; NSC 407010; FSE; 3,3'4'7-tetOH-Flavone; Zante fustic; 3,7,3 ', 4'-tetrahydroxy-flavone C15H10O6 286.24 C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4&prime;,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4&prime; NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4&prime;,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4&#8242;,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058220 breviscapine 5,6,4'-trihydroxyflavone-7-o-beta-d-galactonic acid;scutellarin;5,6,4'-trihydroxyflavone-7-o-β-d-galactonicacid;(2S,3S,4S,5R,6S)-6-[[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-7-chromenyl]oxy]-3,4,5-trihydroxy-2-tetrahydropyrancarboxylic acid; CHEBI:61284; 676536-34-8; 1329-06-2; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-; Flavone, 4',5,6,7-tetrahydroxy-, 7-beta-D-glucopyranuronoside; scutellarin(1-); scutellarein 7-O-beta-D-glucuronate; Scutellarein-7beta-D-glucuronide; AIDS-314104; AIDS314104; 32647-60-2; Scutellarein-7-O-beta-D-glucuronide; Scutellarein-7-glucuronide; Breviscapine; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; 116122-36-2; Breviscapin; MEGxp0_000554; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl; Glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, beta-D-; Scutellarin; Scutellarein-7beta-D-glucuronoside; 27740-01-8; 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranosiduronate; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-keto-chromen-7-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-7-yl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid C21H18O12 462.4 g/mol C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O
TCMBANKIN058221 apigenin 520-36-5; Spectrum2_000428; 10798_FLUKA; Biochem Biophys Res Comm 212: 767 (1997); CCRIS 3789; AIDS001401; apigenin-7-olate; KBioGR_002565; KBio3_002887; BSPBio_000368; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; HSCI1_000221; Flavone, 4',5,7-trihydroxy-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-; EINECS 208-292-3; A3145_SIGMA; 7-hydroxy-2-(4-hydroxyphenyl)-4-oxo-1-benzopyran-5-olate; CHEBI:18388; IDI1_000798; NCGC00025057-04; AIDS-001401; NSC 83244; BPBio1_000406; Apigenol; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NINDS_000798; NCGC00015049-02; 4&prime;,5,7-Trihydroxyflavone; SPBio_002307; Prestwick_719; 2-(4-hydroxyphenyl)-7-oxidanyl-4-oxidanylidene-chromen-5-olate; Spectrum4_001999; Chamomile; KBio1_000798; BRN 0262620; Prestwick2_000414; Prestwick3_000414; SDCCGMLS-0066379.P001; CHEBI:58470; 5,7, 4'-trihydroxyflavone; NCGC00025057-02; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; APIGENIN; Lopac0_000065; K00045; 4&#8242;,5,7-Trihydroxyflavone; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; NCGC00025057-09; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; ACon1_002450; Oprea1_622293; EU-0100065; nchembio790-comp26; 4',5,7-Trihydroxyflavone; NCGC00025057-08; ND-9076; NCGC00025057-01; MEGxp0_000176; Apigenin; 4',5,7-Trihydroxyflavone; apigenin ; Prestwick1_000414; NCGC00015049-01; ZINC00004495; NCGC00025057-05; Spectrum3_001882; BiomolKI_000078; NCI60_041830; Bio1_001354; ghl.PD_Mitscher_leg0.1194; SPECTRUM200846; A828903; DivK1c_000798; 5-18-04-00574 (Beilstein Handbook Reference); 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate; C.I. Natural Yellow 1; 461015-54-3; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)- (9CI); 5,7-dihydroxy-2-(4-hydroxyphenyl)chromone; SMP2_000338; BiomolKI2_000082; Prestwick0_000414; Tocris-1227; Lopac-A-3145; Bio1_000865; NSC83244; Versulin; Pelargidenon 1449; Bio1_000376; Spigenin; 5,7,4'-Trihydroxyflavone; ST056301; UCCF 031; SPBio_000416; Apigenine; C01477; CAS-520-36-5; BSPBio_003384 C15H10O5 270.24 C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
TCMBANKIN058256 salidroside 10338-51-9; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol; SCHEMBL17580247; (2R,3R,4S,5S,6R)-2-[2-(4-hydroxyphenyl)ethoxy]-6-methylol-tetrahydropyran-3,4,5-triol; ACon1_000366; 2-(4-Hydroxyphenyl)ethyl beta-D-glucopyranoside; Glucopyranoside, p-hydroxyphenethyl; Rhodosin; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]tetrahydropyran-3,4,5-triol; MEGxp0_000478; Rhodioloside; beta-D-Glucopyranoside, 2-(4-hydroxyphenyl)ethyl; C14H20O7 300.3 g/mol C1=CC(=CC=C1CCOC2C(C(C(C(O2)CO)O)O)O)O
TCMBANKIN058272 esculetin AIDS-014709; CCG-38509; Cichoriin aglycon; KBioSS_001646; KUC108669N; NSC-26428; ZINC00057908; SM2XD6V944; HMS1570L22; ILEDWLMCKZNDJK-UHFFFAOYSA-N; NSC26428; Esculetol; ZX-AN021876; BPBio1_000968; MolPort-000-709-311; 6,7-Dihydroxycoumarin, 8CI; FCH1117729; ST24044991; 6,7-dihydroxy-2-chromenone; Coumarin, 6,7-dihydroxy-; NCGC00094873-01; KBio1_001374; NCGC00016425-01; Prestwick1_000940; AS-11863; LS-55161; CHEBI:490095; 2H-1-BENZOPYRAN-2-ONE,6,7-DIHYDROXY; RTR-013104; KSC-11-243-1; 7H-1-Benzopyran-7-one, 2,6-dihydroxy-; Esculetol); W-2566; DTXSID3075383; KS-0000017Z; 2,6-Dihydroxy-7H-chromen-7-one; NCGC00016425-04; Cichoriin aglucon; Spectrum5_000512; CD-051; ZX-AFC000486; BG01504928; KSC148K7L; SR-01000721907-2; HMS1921M14; ACM305356; E0386; Aesculetin (cichorigenin; NSC 26428; Aesculetin; s4711; EBD2197580; NCGC00016425-05; NCGC00094873-02; AK591206; AN-44203; BRN 0152788; 6,7-dihydroxy-2H-chromen-2-one; Esculatin; KBio2_006782; AB00489955; GTPL5180; SCHEMBL24641; 6,7-Dihydroxycoumarin; ACMC-20luwt; SR-01000721907; Esculin aglycon; SPECTRUM1500899; MFCD00006874; Cichorigenin; BIB6051; UNII-SM2XD6V944; I14-1622; BDBM34571; ST5306833; CHEMBL244743; TR-013104; MLS000069479; CAS-305-01-1; 6,7-Dihydroxy-2-chromenone; SMR000059055; C09263; 6,7-dihydroxychromen-2-one; esculetin ; HMS3373K09; DivK1c_006430; 3.05E+13; E-3401; HMS2233G24; InChI=1/C9H6O4/c10-6-3-5-1-2-9(12)13-8(5)4-7(6)11/h1-4,10-11; SpecPlus_000334; Spectrum4_001886; MCULE-4460039316; Esculetin; AC1NQYFH; Prestwick2_000940; A820407; Prestwick3_000940; Oprea1_719746; 6,7-bis(oxidanyl)chromen-2-one; Asculetine; ST079379; KBioGR_002416; AIDS014709; AC-18400; AKOS030559695; 91753-33-2; CJ-00486; KBio3_001584; FT-0620854; SMP2_000093; 305-01-1; AB0010898; 5-18-03-00202 (Beilstein Handbook Reference); CE0046; KBio2_001646; BSPBio_000880; Spectrum2_000586; 6,7-Dihydroxy-2H-1-benzopyran-2-one; SC-45867; DB-014626; CC-22332; BSPBio_002364; CTK3G3670; SDCCGMLS-0066669.P001; ALBB-023362; SPBio_000432; AC1Q7980; 6,7-Dihydroxy-2-benzopyrone; Prestwick0_000940; AJ-09788; C-06350; NCGC00016425-03; AK114506; 6,7-Dihydroxycoumarin, 98%; ZINC57908; EINECS 206-161-5; cid_5281416; BRD-K58149231-001-06-9; 2H-1-Benzopyran-2-one, 6,7-dihydroxy-; bmse000986; 4CN-0872; 6,7-dihydroxy-1-benzopyran-2-one; BN0888; HMS2097L22; Bio-0588; SPBio_003049; C9H6O4; E-3400; KBio2_004214; Spectrum_001166; Esculetin, analytical standard; 2H-1-Benzopyran-2-one, 6,7-dihydroxy- (9CI); N1764; 6,7-DIHYDROXYCOUMARIN; Coumarin, 6,7-dihydroxy- Esculetin; J10146; Esculetin, European Pharmacopoeia (EP) Reference Standard; 246573_ALDRICH; ZB002263; Esculin aglucon; 6,7-dihydroxy-coumarin; KB-50565; NCI60_002119; ANW-43483; 6,7-Dihydroxy-2H-chromen-2-one; D0YZ5G; NCGC00016425-06; Jsp005751; AX8020100; AKOS000276955; NCGC00016425-02; CCRIS 7065; 6,7-Dihydroxy-2H-chromen-2-one #; Spectrum3_000752; 6, 7-dihydroxycoumarin; aesculetin; 6,7-dihydroxycoumarin; 6,7-dihydroxy coumarin; CCG-38509; Cichoriin aglycon; KBioSS_001646; KUC108669N; NSC-26428; SM2XD6V944; HMS1570L22; ILEDWLMCKZNDJK-UHFFFAOYSA-N; NSC26428; Esculetol; ZX-AN021876; BPBio1_000968; MolPort-000-709-311; 6,7-Dihydroxycoumarin, 8CI; FCH1117729; ST24044991; Coumarin, 6,7-dihydroxy-; NCGC00094873-01; KBio1_001374; NCGC00016425-01; Prestwick1_000940; AS-11863; LS-55161; CHEBI:490095; 2H-1-BENZOPYRAN-2-ONE,6,7-DIHYDROXY; RTR-013104; KSC-11-243-1; 7H-1-Benzopyran-7-one, 2,6-dihydroxy-; Esculetol); W-2566; DTXSID3075383; KS-0000017Z; 2,6-Dihydroxy-7H-chromen-7-one; NCGC00016425-04; Cichoriin aglucon; Spectrum5_000512; CD-051; ZX-AFC000486; BG01504928; KSC148K7L; SR-01000721907-2; HMS1921M14; ACM305356; E0386; Aesculetin (cichorigenin; NSC 26428; Aesculetin; s4711; EBD2197580; NCGC00016425-05; NCGC00094873-02; AK591206; AN-44203; BRN 0152788; Esculatin; KBio2_006782; AB00489955; GTPL5180; SCHEMBL24641; ACMC-20luwt; SR-01000721907; Esculin aglycon; SPECTRUM1500899; MFCD00006874; Cichorigenin; BIB6051; UNII-SM2XD6V944; I14-1622; BDBM34571; CHEMBL244743; TR-013104; MLS000069479; CAS-305-01-1; 6,7-Dihydroxy-2-chromenone; SMR000059055; C09263; 6,7-dihydroxychromen-2-one; HMS3373K09; DivK1c_006430; 3.05E+13; E-3401; HMS2233G24; InChI=1/C9H6O4/c10-6-3-5-1-2-9(12)13-8(5)4-7(6)11/h1-4,10-11; SpecPlus_000334; Spectrum4_001886; MCULE-4460039316; Esculetin; AC1NQYFH; Prestwick2_000940; A820407; Prestwick3_000940; Oprea1_719746; 6,7-bis(oxidanyl)chromen-2-one; Asculetine; ST079379; KBioGR_002416; AC-18400; AKOS030559695; 91753-33-2; CJ-00486; KBio3_001584; FT-0620854; SMP2_000093; 305-01-1; AB0010898; 5-18-03-00202 (Beilstein Handbook Reference); CE0046; KBio2_001646; BSPBio_000880; Spectrum2_000586; 6,7-Dihydroxy-2H-1-benzopyran-2-one; SC-45867; DB-014626; CC-22332; BSPBio_002364; CTK3G3670; SDCCGMLS-0066669.P001; ALBB-023362; SPBio_000432; AC1Q7980; 6,7-Dihydroxy-2-benzopyrone; Prestwick0_000940; AJ-09788; C-06350; NCGC00016425-03; AK114506; 6,7-Dihydroxycoumarin, 98%; ZINC57908; EINECS 206-161-5; cid_5281416; BRD-K58149231-001-06-9; 2H-1-Benzopyran-2-one, 6,7-dihydroxy-; bmse000986; 4CN-0872; 6,7-dihydroxy-1-benzopyran-2-one; BN0888; HMS2097L22; Bio-0588; SPBio_003049; C9H6O4; E-3400; KBio2_004214; Spectrum_001166; Esculetin, analytical standard; 2H-1-Benzopyran-2-one, 6,7-dihydroxy- (9CI); N1764; 6,7-DIHYDROXYCOUMARIN; Coumarin, 6,7-dihydroxy- Esculetin; J10146; Esculetin, European Pharmacopoeia (EP) Reference Standard; ZB002263; Esculin aglucon; 6,7-dihydroxy-coumarin; KB-50565; NCI60_002119; ANW-43483; 6,7-Dihydroxy-2H-chromen-2-one; D0YZ5G; NCGC00016425-06; Jsp005751; AX8020100; AKOS000276955; NCGC00016425-02; CCRIS 7065; 6,7-Dihydroxy-2H-chromen-2-one #; Spectrum3_000752 C9H6O4 178.14 g/mol C1=CC(=O)OC2=CC(=C(C=C21)O)O
TCMBANKIN058310 cinnamaldehyde trans-Cinnamaldehyde, >=98%, FCC, FG; (E)-3-phenylacrolein; DSSTox_GSID_24834; 3-Phenyl-2-propenal; LS-378; UNII-SR60A3XG0F; (3E)-3-phenylprop-2-enal; Cinnamal; ZINC1532777; CS-0009609; (trans)-cinnamaldehyde; NSC-16935; NCGC00091512-02; NSC 16935; ST50213393; D0PJ3M; Aldehyd skoricovy; MolPort-004-288-292; Abion CA; BRN 1071571; 2-propenal, 3-phenyl-, (2E)-; trans-3-Phenylacrolein; FEMA No. 2286; transcinnamaldehyde; Cinnamaldehyde, trans-; Cinnamic aldehyde; DTXSID6024834; 3-Phenylpropenal; 3-Phenyl-2-propen-1-al; 3-phenylprop-2-enal; Cinnamaldehyde (trans), neat; AIDS-097032; BB_NC-2240; trans-Cinnamic aldehyde; NSC40346; TRANS-CINNAMALDEHYDE (SEE ALSO CINNAMALDEHYDE (104-55-2)); CCRIS 6222; trans-3-Phenyl-2-propenal; 3-Fenylpropenal [Czech]; CCRIS 3189; BBL010378; MLS002454394; SCHEMBL3441; NCGC00091512-05; ST5213393; AIDS097032; CNMA; CAS-14371-10-9; Zimtaldehyde; (2E)-3-phenylprop-2-enal; Cinnamaldehyde, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4; NCGC00259353-01; 2-Propenal, 3-phenyl-, (E)- (9CI); Cassia aldehyde; 3-Phenylacrylaldehyde; 3-Phenylacrolein; NCGC00257017-01; M181; SR60A3XG0F; W228605_ALDRICH; 14371-10-9; Hefty Dog and Cat Repellent; trans cinnamic aldehyde; (E)-Cinnamic aldehyde; NCI-C56111; NSC16935; BDBM50203065; 2-Propenal, 3-phenyl-; (2E)-3-phenylacrylaldehyde; AK-77787; A801001; trans-Cinnamaldehyde, >=99%; GTPL2423; CINNAMALDEHYDE (TRANS); AS-12078; Benzylideneacetaldehyde; Cinnamaldehyde [NF]; BRN 0605737; DB-003796; AC1LCUDE; 58840-EP2308879A1; trans-3-Phenylacrylaldehyde; 2-propenal,3-phenyl-,(E)-; NSC-40346; TR-001003; Tox21_111144; W228613_ALDRICH; 58840-EP2305682A1; STK397371; (2E)-3-Phenyl-2-propenal; KB-81236; NCGC00091512-06; C00903; cinnamaldehyde ; Cinnamaldehyde, (E)-; trans-Cinnamaldehyde, 99%; Tox21_201804; 2-Propenal, 3-phenyl-, (E)-; AK158901; AI3-00473; (E)-3-Phenyl-2-propenal; 104-55-2; MFCD00007000; 96320_FLUKA; R501736; ST24024694; (E)-3-phenyl-acrylaldehyde; 239968_ALDRICH; AJ-26812; Phenylacrolein; trans-Cinnamaldehyde; Aldehyd skoricovy [Czech]; ST2407775; W-205597; Cinnamylaldehyde; LS-850; EINECS 203-213-9; AC1Q6PPL; RL00215; ZINC01532777; ACN-035400; bmse010257; 4-07-00-00984 (Beilstein Handbook Reference); C9H8O; (E)-3-Phenyl-propenal; trans-Cinnamaldehyde, analytical standard; Cinnamic aldehyde (natural); NCGC00091512-07; trans-Cinnamylaldehyde; Tox21_303271; EC 203-213-9; C80687_ALDRICH; EPA Pesticide Chemical Code 040506; Cinnamyl aldehyde; RTR-001003; SMR000112334; AN-24684; beta-phenylacrolein; cinnamic aldehyde, (E)-isomer; CHEBI:16731; WLN: VH1U1R; I14-109742; (E)-3-phenylacrylaldehyde; RT-001454; I14-7336; 2-07-00-00273 (Beilstein Handbook Reference); Epitope ID:150921; trans-Cinnamaldehyde; trans-3-Phenylacrylaldehyde; NCGC00091512-01; DSSTox_RID_77548; AC1Q6BJW; trans cinnamaldehyde; CHEMBL293492; SBB028652; (E)-3-phenyl-2-propenal(E)-cinnamaldehyde; 3-Fenylpropenal; (E)-phenylvinyl aldehyde; trans-Cinmaldehyde; KJPRLNWUNMBNBZ-QPJJXVBHSA-N; Nat. Cinnamaldehyde; (E)-Cinnamaldehyde; NATURAL CINNAMIC ALDEHYDE; FEMA Number 2286; HMS2268O08; AKOS000119171; Cinnemaldehyde; beta-Phenylcrolein; SC-19143; HSDB 209; B99DD6C7-1C6D-4FE3-A172-54BFDB987683; 3-PHENYL-2-PROPENAL (TRANS); CINNAMALDEHYDE; Cinnamaldehyde, Vetec(TM) reagent grade, 93%; AI3-33275; NCGC00091512-04; e-cinnamaldehyde; Cinnamaldehyde, natural, >=95%, FG; (E)-3-phenylprop-2-enal; Acrolein, 3-phenyl-; AM20060482; BG01497386; 3-Phenyl-2-propenaldehyde; N1482; Cinnamaldehyde, 95% 100g; KB-76097; Caswell No. 221A; CINNAMALDEHYDE (SEE ALSO TRANS-CINNAMALDEHYDE (14371-10-9)); CJ-24256; DSSTox_CID_4834; MolPort-000-871-213; (E)-3-Phenylpropenal; Cinnamaldehyde, Natural; Trans- cinnamic aldehyde;(E)-Cinnamaldehyde;3-phenylpropenal;3-phenyl-2-propenalTrans- cinnamic aldehyde;(E)-Cinnamaldehyde;3-phenylpropenal;3-phenyl-2-propenal C9H8O 132.16 C1=CC=C(C=C1)C=CC=O
TCMBANKIN058322 baicalein 5,6,7-trihydroxyflavanone; KBio3_002435; NCGC00025282-03; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; AIDS-000731; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; baicalein ; Sho-saiko-to; 5,6,7-trihydroxy-2-phenylchromen-4-one; ST057152; Spectrum_000427; SPECTRUM1504002; 5,6,7-trihydroxy-2-phenyl-chromone; KBio1_001798; KBio2_006043; NSC 661431; 11712_FLUKA; SDCCGMLS-0066744.P001; KBioSS_000907; CHEBI:2979; SMP1_000037; 5,6,7-trihydroxy-2-phenyl-4-chromenone; LMPK12140610; SPBio_000572; NCGC00025282-02; Dihydrobaicalein; Baicalein; 5,6,7-trihydroxy-2-phenyl-chroman-4-one; Spectrum4_000537; KBioGR_001173; 491-67-8; NCGC00017236-01; S00113; 465119_ALDRICH; Spectrum5_001418; Oprea1_765614; Tocris-1761; DivK1c_006854; NSC729192; AIDS000731; BSPBio_003215; SCHEMBL12068882; 5,6,7-Trihydroxyflavone; Spectrum3_001608; KBio2_003475; SpecPlus_000758; 5,6,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one; NSC661431; NCGC00025282-01; 5,6,7-trihydroxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one; C10023; Spectrum2_000466; TNP00121; KBio2_000907; ZINC00017881; Biacalein; 5,6,7-trihy-droxyflavone C15H10O5 270.24 g/mol C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O
TCMBANKIN058519 (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (&#8722;)-Epigallocatechin gallate; EGCG; SPBio_000035; (&#8722;)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (&#8722;)-cis-3,3&#8242;,4&#8242;,5,5&#8242;,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate C22H18O11 458.4g/mol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
TCMBANKIN058802 cudraflavone b;Mulberrochromene CHEMBL221907; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[5,6-g]chromen-4-one; 8-(2,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-2H,6H-pyrano[3,2-g]chromen-6-one; cid_5319925; 2-(2,4-dihydroxy-phenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-but-2-enyl)-8H-pyrano[3,2-g]chromen-4-one; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)-4-pyrano[5,6-g]chromenone; BDBM50193718; MLS000697596; mulberrochromene; AC1NSYTH; cudraflavone B; 8-(2,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-7-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one; HMS2268D05; SMR000470934; CHEBI:67850; 19275-49-1; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-4(8H)-one C25H24O6 420.5 g/mol CC(=CCC1=C(OC2=CC3=C(C=CC(O3)(C)C)C(=C2C1=O)O)C4=C(C=C(C=C4)O)O)C
TCMBANKIN059159 capsaicin 8-Methyl-N-vanillyl-6-nonenamide, (E)-; AKOS007930159; Bio-0615; GTPL2486; Bio2_000748; EPA Pesticide Chemical Code 070701; Zostrix HP; S07O44R1ZM; TC-030399; 360376_ALDRICH; NCGC00017337-07; Citrus Aurantium 30%; AK589917; ZOSTRIX (TN); HMS2230O23; D0U5CE; HMS1989N10; IDI1_034018; DSSTox_GSID_20241; Isodecenoic acid vanillylamide; NGX-7325; NCGC00017337-04; HMS1791N10; NCGC00090853-08; NCGC00090853-11; KBio3_000536; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); NSC-757844; M2028_SIGMA; E-CAPSAICIN; Capsaicin, from Capsicum sp., >=50% (HPLC); (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; MCULE-8056866140; Capsaicin [USP:INN]; NCGC00257869-01; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; DB06774; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; SMR000718774; KBioGR_000268; MEGxp0_001448; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; Caswell No. 158; Prestwick2_000879; KBio1_000354; FEMA No. 3404; Capsaicin, analytical standard; N735; HMS3649N15; SBI-0052593.P002; AJ-26667; BRD-K50590187-001-06-6; CAS_404-86-4; NCGC00017337-02; HMS1921H11; 8-Methyl-N-vanillyl-trans-6-nonenamide; 21750_FLUKA; ZINC01530575; Vanilloid; YKPUWZUDDOIDPM-SOFGYWHQSA-N; MR3H3; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; HMS1570P19; capsaicin ; Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8 -methyl-, (E)-; KBio3_000535; Zostrix (TN); KBio2_000783; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; NCGC00017337-06; Capsaicin, European Pharmacopoeia (EP) Reference Standard; Capsicin; N-(3-Methoxy-4-hydroxybenzyl)-8-methyl-6-nonenamide; KBioSS_000783; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; Bitter orange extract 30%; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; SR-05000001861-5; Capsaicin, certified reference material, TraceCERT(R); CAPSAICIN, NATURAL; DSSTox_RID_75455; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; depletes Substance P; trans-8-Methyl-N-vanillyl-6-nonenamide; BDBM20461; MolPort-001-742-263; 1217899-52-9; NCGC00090853-03; SR-05000001861; Spectrum_000303; UPCMLD-DP092:001; Capsaicin, >=95%, from Capsicum sp.; Capsaicin (transdermal patch formulation, neuropathic pain); I01-2469; Nonenamide, 8-methyl-N-vanillyl-, (E)-; SR-05000001861-9; CC0144; Transacin; AC1Q46B3; SDCCGMLS-0066678.P001; SR-05000001861-6; Axsain; AN-23437; (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; (E)-N-(4-Hydroxy-3-methoxybenzyl); (E)8-methyl-N-vanillyl-6-Nonenamide; CCRIS 1588; Capsaicin (JAN/USP); Capsaicin (Natural); trans-Capsaicin-d3; N0C781; trans-8-Methyl-N-vanillylnon; M1149; SC-19636; (E)-N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Styptysat; HMS2097P19; NCGC00017337-11; KBio3_002417; neurotoxic; CHEMBL294199; Capsaicin (in oleoresin of capsicum); NCGC00090853-01; N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Capsaicin [USAN]; Capsicine; NCGC00017337-08; NCGC00017337-09; C06866; N-[(4-hydroxy-3-methoxy-phenyl)methyl]nonanamide; NGX-1998; Tox21_110817; SCHEMBL8086; UNII-S07O44R1ZM; NSC 56353; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; BDBM86537; LMFA08020085; N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; KBio2_002836; trans-8-methyl-N-vanillyl-6-nonenamide; NCGC00090853-06; CHEBI:94524; NCGC00090853-09; NCGC00090853-02; Bio2_000268; HMS3402N10; Prestwick_204; Prestwick3_000879; 8-Methyl-N-vanillyl-6E-nonenamide; Spectrum4_001739; 8-Methyl-N-Vanillyl-6-Nonenamide; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; BSPBio_001548; LS-2138; Capsaicin, United States Pharmacopeia (USP) Reference Standard; KBioGR_002158; EINECS 206-969-8; Bio1_000468; SPBio_002878; KBio2_000268; MFCD00017259; Bio1_001446; nchembio862-comp2; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; NSC-56353; NSC757844; DTXSID9020241; Ausanil; HMS501B16; HMS2092D21; EI-125; NCGC00090853-04; AK113598; NCI-C56564; Qutenza; SR-05000001861-4; [(E)-N-(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; Adlea; MLS002154049; (E)-8-Methyl-N-vanillyl-6-nonenamide; Pharmakon1600-01501128; Spectrum5_000538; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; 6-Nonenamide, (E)-; SCHEMBL8085; AB00053098-11; Capsaicin [in oleoresin of capsicum]; CJ-23980; NCGC00017337-12; HSDB 954; NGX 4010; CAS-404-86-4; BRN 2816484; 4CH-016296; NSC56353; IDI1_000354; RTC-030399; (E)-Capsaicin; TL8002946; NCGC00017337-05; CS-1518; Mioton; BG01597556; DivK1c_000354; 12084_FLUKA; Bio1_000957; AC-10114; AC1LU7K3; UPCMLD-DP092; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; TQ-1018; FT-0082538; Zostrix; NCGC00017337-03; AB00053098_12; SPECTRUM1501128; KS-5181; Prestwick1_000879; Capsaicin, from natural source; NCGC00017337-13; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; Spectrum2_000770; NSC_2548; Prestwick0_000879; BPBio1_001053; NCGC00090853-10; C18H27NO3; NCGC00090853-12; W-5044; CAPSAICINE; SR-05000001861-1; Tox21_200315; HMS1361N10; D00250; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Spectrum3_001449; HY-10448; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; BSPBio_002917; ST057183; KBio2_005919; ZINC1530575; SPBio_000820; N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NCGC00017337-10; CCG-39908; STL372889; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; Capsaicin Patch; UPCMLD-DP092:002; NGX-3781; BBL027836; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; Capsaicin (8-Methyl-N-vanillyl-6-nonenamide); 912457-62-6; HMS2089N11; Capsaicin; epsilon-capsaicin; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NGX-4010; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)- (8CI); KBioSS_000268; 21748_FLUKA; Citrus Aurantium Extract; KBio2_005404; TNP00277; trans-Capsaicin; CHEBI:3374; Capsaicin(Qutenza); CITRUS AURANTIUM PE; CAPSAICIN (2444-46-4 NONIVAMIDE (SYNTHETIC CAPSAICIN)); N1667; BSPBio_000957; 4-13-00-02588 (Beilstein Handbook Reference); BRD-K37056290-001-01-1; KBio2_003351; NCGC00090853-07; SMP2_000337; NINDS_000354; Isodecenoate; DSSTox_CID_241; ALGRX 4975; 404-86-4; CAPSAICINOIDS;Vanilloid;campsiol;capsaicin C18H27NO3 305.41 CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
TCMBANKIN059258 dihydrocapsacine Dihydrocapsaicin; CHEBI:46932; Nonanamide, 8-methyl-N-vanillyl-; ZINC02522581; A813700; M1022_SIGMA; N-[(4-Hydroxy-3-methoxy-phenyl)methyl]-8-methyl-nonanamide; N-(4-hydroxy-3-methoxybenzyl)-8-methylnonanamide; N-[(3-methoxy-4-oxidanyl-cyclohexa-2,4-dien-1-yl)methyl]-8-methyl-non-6-enamide; NCGC00094119-02; TNP00314; ST057532; dihydrocapsaicin; 19408-84-5; 6,7-Dihydrocapsaicin; EU-0100782; NCGC00015645-01; N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-pelargonamide; N-[(4-hydroxy-3-methoxy-1-cyclohexa-2,4-dienyl)methyl]-8-methyl-6-nonenamide; 8-Methyl-N-vanillylnonanamide; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methylnonanamide; BRN 2815150; Dihydrocapsacine; Nonanamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl- (9CI); Lopac0_000782; N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnonanamide; NCGC00015645-02; Lopac-M-1022; CCRIS 1589 C18H29NO3 307.4 g/mol CC(C)CCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
TCMBANKIN059336 tauroursodeoxycholic acid tauroursodeoxycholicacid; ursodeoxycholicacid; ursodeoxycholic acid C26H45NO6S 499.7 g/mol CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
TCMBANKIN059452 ethyl aldehyde C2H4O 44.05 g/mol CC=O
TCMBANKIN059684 Vitamin E β- C29H50O2 430.79 CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746 α-tocopherol C29H50O2 430.7 g/mol CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C
TCMBANKIN060080 isoandrographolide;12-dideoxyhydro-andrographolide;andrographolide C20H30O5 350.45 CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O
TCMBANKIN060117 iso-alantolactone C15H20O2 232.32 CC12CCCC(=C)C1CC3C(C2)OC(=O)C3=C
TCMBANKIN060497 dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN060645 lovastatin C24H36O5 404.5 g/mol CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
TCMBANKIN060811 Di(2-ethylhexyl)phthalate;Ethylhexyl phthalate;phthalic acid bis-(2-ethyl-hexyl)ester;bis(2-ethyl-hexyl)-phthalate;Octoil C24H38O4 390.6 g/mol CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC
TCMBANKIN060889 delta(9)-tetrahydrocannabinol C21H30O2 314.5 g/mol CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O
TCMBANKIN060892 tetrahydrocannabinol delta8 CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O
TCMBANKIN061371 nicotine 36733_RIEDEL; 2yk1; CHEBI:59806; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine; (2S)-1-methyl-2-(pyridin-3-yl)pyrrolidinium; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; D03365; 54-11-5; NCGC00090693-03; 46343_RIEDEL; C00745; Nicotine; NCGC00090693-04; AIDS-156031; 65-31-6 (R,R-BITARTRATE); (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; Habitrol (TN); SBB012359; N5511_SIGMA; (&#8722;)-Nicotine; Nicotine (compounds related to); PDSP2_000555; NCT; N3876_SIGMA; 3-[(2S)-1-methyl-2-pyrrolidinyl]pyridine; NCGC00090693-01; ZB012057; (S)-(-)-nicotine; CHEBI:17688; SDCCGMLS-0066911.P001; (S)-nicotinium(1+); AC1OCG5J; 3-(2-(N-methylpyrrolidinyl))pyridine; NSC97238 (R,R-BITARTRATE SALT); 3-[(2S)-1-methylpyrrolidin-1-ium-2-yl]pyridine; (S)-nicotinium cation; AIDS156031; NCGC00090693-05; PDSP1_000465; PDSP1_000113; PDSP2_000463; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; Nicotine (USP); 54-11-5 (FREE BASE); L(-)-nicotine; (&#8722;)-Nicotine solution C10H14N2 162.23 g/mol CN1CCCC1C2=CN=CC=C2
TCMBANKIN061383 Phenylephrine Carney glycosides C9H13NO2 167.2 g/mol CNCC(C1=CC(=CC=C1)O)O
TCMBANKIN061496 calycosin HSDB 8109; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one; CHEBI:17793; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 09N3E8P7TA; calycosin (OLD); 20575-57-9; HY-N0519; ZINC6018563; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one; 3'-hydroxy-formononetin; calycosin ; LMPK12050056; MEGxp0_001325; BRD-K05039497-001-01-6; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',7-dihydroxy-4'-methoxy-isoflavone; AKOS015896719; UNII-09N3E8P7TA; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-; 3', 7-dihydroxy-4'-methoxyisoflavone; 575C579; C01562; HMS2268B05; C-17889; MolPort-001-741-659; Calycosin; X1103; SCHEMBL73013; Q-100254; AC1NQX1G; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromen-4-one; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4-chromenone; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromone; CHEMBL241608; CS-3715; ZZAJQOPSWWVMBI-UHFFFAOYSA-N; BG01576591; MLS000876988; DTXSID70174580; 3',7-dihydroxy-4'-methoxyisoflavone; ACon1_000650; I07-0176; NP-004576; NCGC00169494-01; 3-(4-methoxy-3-oxidanyl-phenyl)-7-oxidanyl-chromen-4-one; MCULE-7559555984; 7,3'-dihydroxy-4'-methoxyisoflavone; A814711; N1412; 3'-hydroxyformononetin; FT-0630465; MFCD00210598; SMR000440659; AN-8397; AC-8043; 3',7-dihydroxy-4'-methoxy-isoflavone C16H12O5 284.26 g/mol COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O
TCMBANKIN061570 curcumin (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin IC21H20O6 368.4 g/mol COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
TCMBANKIN061675 berberime berberine ; isoquinoline alkaloid; berberine C20H18NO4+ 336.4 g/mol COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC
TCMBANKIN061781 hernandin 69222-20-4 (UNSPECIFIED); AIDS006791; Deoxypodophyllotoxin; AIDS-006791; (5aR,8aR,9R)-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofurano[5,6-f][1,3]benzodioxol-8-one; (-)-Deoxypodophyllotoxin; (-)-Anthricin; Hernandin; Anthricin; DPT; Podophyllotoxin, deoxy-; SILICICOLIN; Desoxypodophyllotoxin; Anthriscin; NCI60_003794; (-)-Desoxypodophyllotoxin; 19186-35-7; 19186-35-7 (5R,5AR,8AR); Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(3,4,5-trimethoxyphenyl)-,(5R,5aR,8aR)-; 5,8,8a,9,-Tetrahydro-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; NSC403148; Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR)-; C10556; 4-Deoxypodophyllotoxin; deoxypodophyllotoxin; (-)-deoxypodophyllotoxin; anthricin isomer; isoanthricin; anthricin C22H22O7 398.4 g/mol COC1=CC(=CC(=C1OC)OC)C2C3C(CC4=CC5=C(C=C24)OCO5)COC3=O
TCMBANKIN061938 sulforathane sulforaphane C6H11NOS2 177.3 g/mol CS(=O)CCCCN=C=S

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000002 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI000009 Neoplasms Abnormality of the nervous system; Neoplasm Neoplastic Process disease
TCMBANKDI000018 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000044 Infections - Disease or Syndrome group
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000076 Neoplasms - Neoplastic Process group
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI000092 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI000294 Neoplasms - Neoplastic Process disease
TCMBANKDI000633 Skin and Connective Tissue Diseases; Musculoskeletal Diseases - Disease or Syndrome group
TCMBANKDI000653 Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI000891 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI001279 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI001299 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI001688 - - Disease or Syndrome phenotype
TCMBANKDI001841 Neoplasms - Neoplastic Process disease
TCMBANKDI001856 Pathological Conditions, Signs and Symptoms; Digestive System Diseases - Disease or Syndrome disease
TCMBANKDI001926 Neoplasms - Neoplastic Process disease
TCMBANKDI001958 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI002025 Cardiovascular Diseases; Wounds and Injuries Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI002231 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI002624 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI004054 Pathological Conditions, Signs and Symptoms - Neoplastic Process phenotype
TCMBANKDI004208 Neoplasms Neoplasm; Abnormality of the breast Neoplastic Process disease
TCMBANKDI004344 Nervous System Diseases; Endocrine System Diseases - Disease or Syndrome group
TCMBANKDI004983 Neoplasms; Female Urogenital Diseases and Pregnancy Complications - Neoplastic Process disease
TCMBANKDI005370 Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Constitutional symptom; Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI005539 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases - Neoplastic Process disease
TCMBANKDI006055 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI006084 Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI006328 - Abnormality of the genitourinary system Disease or Syndrome phenotype
TCMBANKDI006612 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI006641 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI006652 Nutritional and Metabolic Diseases; Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI006733 Pathological Conditions, Signs and Symptoms - Sign or Symptom phenotype
TCMBANKDI006861 Neoplasms Neoplasm; Abnormality of the musculature Neoplastic Process disease
TCMBANKDI006934 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI007091 Neoplasms - Neoplastic Process phenotype
TCMBANKDI007296 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI007679 Digestive System Diseases; Neoplasms - Neoplastic Process; Experimental Model of Disease disease
TCMBANKDI007737 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI007782 Neoplasms - Neoplastic Process disease
TCMBANKDI007899 - - Neoplastic Process disease
TCMBANKDI008105 Infections; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI008314 Eye Diseases - Disease or Syndrome disease
TCMBANKDI009152 - - Congenital Abnormality disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI009657 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality group
TCMBANKDI009702 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome phenotype
TCMBANKDI009727 Infections - Disease or Syndrome disease
TCMBANKDI010048 Infections; Respiratory Tract Diseases Abnormality of the immune system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI010160 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI010214 - - Neoplastic Process disease
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011264 Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases - Disease or Syndrome disease
TCMBANKDI011315 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI011480 Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI012074 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI012119 Pathological Conditions, Signs and Symptoms Abnormality of the nervous system Cell or Molecular Dysfunction phenotype
TCMBANKDI012157 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome group
TCMBANKDI012424 Pathological Conditions, Signs and Symptoms; Neoplasms - Pathologic Function phenotype
TCMBANKDI012976 Neoplasms; Stomatognathic Diseases - Neoplastic Process disease
TCMBANKDI013148 Respiratory Tract Diseases; Nervous System Diseases Abnormality of the nervous system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI013313 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI013321 Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI013347 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI013356 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI013495 Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI013745 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI013839 Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI014088 Respiratory Tract Diseases; Cardiovascular Diseases Abnormality of the respiratory system; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI014531 Pathological Conditions, Signs and Symptoms; Neoplasms; Musculoskeletal Diseases - Neoplastic Process disease
TCMBANKDI015290 Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of the cardiovascular system Pathologic Function disease
TCMBANKDI015310 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI015449 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI015452 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI015780 - - Disease or Syndrome disease
TCMBANKDI016026 Neoplasms; Eye Diseases Neoplasm; Abnormality of the eye Neoplastic Process disease
TCMBANKDI016159 Infections; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI016467 Female Urogenital Diseases and Pregnancy Complications - Disease or Syndrome disease
TCMBANKDI016800 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI016890 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI016946 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017474 - - Disease or Syndrome disease
TCMBANKDI017642 Neoplasms Abnormality of the integument; Neoplasm Neoplastic Process disease
TCMBANKDI017700 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018017 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Sign or Symptom phenotype
TCMBANKDI018958 Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI019879 Digestive System Diseases; Neoplasms; Endocrine System Diseases - Neoplastic Process disease
TCMBANKDI020257 Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI020451 Neoplasms - Neoplastic Process disease
TCMBANKDI020603 Pathological Conditions, Signs and Symptoms - Anatomical Abnormality phenotype
TCMBANKDI020782 Infections - Disease or Syndrome group
TCMBANKDI020794 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI021033 - - Congenital Abnormality disease
TCMBANKDI021455 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI022022 - - Disease or Syndrome disease
TCMBANKDI022433 Respiratory Tract Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI022473 Neoplasms - Neoplastic Process disease
TCMBANKDI022574 Chemically-Induced Disorders; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI022610 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases Abnormality of the digestive system Congenital Abnormality disease
TCMBANKDI023140 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI023437 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI024098 Skin and Connective Tissue Diseases - Disease or Syndrome group
TCMBANKDI024262 - - Neoplastic Process phenotype
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI024875 Nutritional and Metabolic Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI025368 Infections; Nervous System Diseases; Mental Disorders - Disease or Syndrome disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI026459 Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI026556 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI027026 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI027289 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms - Mental or Behavioral Dysfunction disease
TCMBANKDI027339 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI027628 Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI027640 Infections - Disease or Syndrome group
TCMBANKDI027682 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI027705 Pathological Conditions, Signs and Symptoms; Infections - Pathologic Function phenotype
TCMBANKDI028533 - Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI028640 Neoplasms - Neoplastic Process disease
TCMBANKDI028799 Eye Diseases - Disease or Syndrome disease
TCMBANKDI029520 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI029614 - - Disease or Syndrome disease
TCMBANKDI029701 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI029791 Nutritional and Metabolic Diseases - Disease or Syndrome phenotype
TCMBANKDI029861 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI029922 Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI030041 Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI030204 - - Neoplastic Process disease
TCMBANKDI030206 Female Urogenital Diseases and Pregnancy Complications - Pathologic Function phenotype
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI030653 Neoplasms - Neoplastic Process disease
TCMBANKDI030678 Digestive System Diseases; Neoplasms - Neoplastic Process group
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI031381 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI031522 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI031651 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI032193 Behavior and Behavior Mechanisms Abnormality of the nervous system Mental or Behavioral Dysfunction phenotype
TCMBANKDI032222 Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease